{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:30:47Z","timestamp":1758709847993},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fa. Celgene","award":["D-151640-025-012"],"award-info":[{"award-number":["D-151640-025-012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-grade B cell lymphomas with rearrangements on C-MYC and BCL2 and\/or BCL6 (HGBL with MYC and BCL2 and\/or Bcl6 rearrangement) are associated with worse clinical outcomes and thus were introduced as a separate new category in the recently updated WHO classification. From 2012 to 2016, we analyzed a consecutive cohort of large B cell lymphomas (LBCLs) for C-MYC, BCL2, and BCL6 rearrangements and correlated our results with clinical-pathological parameters. Ten of 78 (13%) cases had a C-MYC and BCL2 and\/or BCL6 rearrangement, so-called double or triple hit (DH), while double\/triple copy number gains (CNGs) were found in eight (10%) patients. Patients with a high-grade lymphoma with DH or CNG progressed significantly more often after first-line chemotherapy (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). When treated with standard chemotherapy, patients with a DH or CNG had a significantly worse overall (OS) and recurrence free survival (RFS) compared with all other patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.033 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively). Thus, patients with a diffuse large B cell lymphoma, harboring a double\/triple CNG, seem to have a similar poor prognosis than those with a DH. Though our data can only be regarded as preliminary, our results warrant further investigations to fully elucidate the role of CNGs as well as underlying molecular mechanisms resulting in aggressive behavior in LBCL.<\/jats:p>","DOI":"10.1007\/s00277-020-04124-0","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T07:53:04Z","timestamp":1593589984000},"page":"2125-2132","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patients with double\/triple copy number gains on C-MYC, BCL2, and\/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and\/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas"],"prefix":"10.1007","volume":"99","author":[{"given":"Ella","family":"Willenbacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Weger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf","family":"Dominik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Manzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"issue":"9","key":"4124_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.5858\/arpa.2014-0451-CP","volume":"139","author":"DP O\u2019Malley","year":"2015","unstructured":"O\u2019Malley DP, Auerbach A, Weiss LM (2015) Practical applications in immunohistochemistry: evaluation of diffuse large B-cell lymphoma and related large B-cell lymphomas. Arch Pathol Lab Med 139(9):1094\u20131107","journal-title":"Arch Pathol Lab Med"},{"key":"4124_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J eds (2008) WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 194\u201395. World Health Organization Classification of Tumours; Vol 2"},{"issue":"19","key":"4124_CR3","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri SA, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019\u20135032","journal-title":"Blood"},{"key":"4124_CR4","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.V120.21.1619.1619","volume":"120","author":"JS Abramson","year":"2012","unstructured":"Abramson JS, Barnes JA, Feng Y, Takvorian T, Neuberg D, Hochberg EP, Sohani AR (2012) Double hit lymphomas: evaluation of prognostic factors and impact of therapy. Blood 120:1619","journal-title":"Blood"},{"issue":"1","key":"4124_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0609.2012.01787.x","volume":"89","author":"M\u00d8 Pedersen","year":"2012","unstructured":"Pedersen M\u00d8, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Gang UO, N\u00f8rgaard P (2012) Double-hit BCL2\/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre\u2019s experience. Eur J Haematol 89(1):63\u201371","journal-title":"Eur J Haematol"},{"issue":"6","key":"4124_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bjh.12982","volume":"166","author":"Y Oki","year":"2014","unstructured":"Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR (2014) Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891\u2013901","journal-title":"Br J Haematol"},{"issue":"45","key":"4124_CR7","doi-asserted-by":"publisher","first-page":"78245","DOI":"10.18632\/oncotarget.20794","volume":"8","author":"DJ Landsburg","year":"2017","unstructured":"Landsburg DJ (2017) Advancing the management of double hit lymphoma. Oncotarget 8(45):78245\u201378246","journal-title":"Oncotarget"},{"issue":"28","key":"4124_CR8","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452\u20133459","journal-title":"J Clin Oncol"},{"issue":"6","key":"4124_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.13276","volume":"168","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Oki Y, Westin JR, Turturro F (2015) A clinician\u2019s guide to double hit lymphomas. Br J Haematol 168(6):784\u2013795","journal-title":"Br J Haematol"},{"issue":"1","key":"4124_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","volume":"2014","author":"SH Swerdlow","year":"2014","unstructured":"Swerdlow SH (2014) Diagnosis of \u2018double hit\u2019 diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program 2014(1):90\u201399","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"4124_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/leu.2015.34","volume":"29","author":"S Momose","year":"2015","unstructured":"Momose S, Wei\u00dfbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger AM, Ott G, Rosenwald A (2015) The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 29(8):1789\u20131791","journal-title":"Leukemia"},{"issue":"20","key":"4124_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"12","key":"4124_CR13","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/modpathol.2017.93","volume":"30","author":"AE Quesada","year":"2017","unstructured":"Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, Wei P, Tang G, Seegmiller AC, Reddy NM, Yin CC, Wang W, Xu J, Miranda RN, Zuo Z, Li S (2017) Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol 30(12):1688\u20131697","journal-title":"Mod Pathol"},{"key":"4124_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/modpathol.2014.95","volume":"28","author":"S Li","year":"2015","unstructured":"Li S, Seegmiller AC, Lin P, Wang XJ, Miranda RN, Bhagavathi S, Medeiros LJ (2015) B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas. Mod Pathol 28:208\u2013217","journal-title":"Mod Pathol"},{"key":"4124_CR15","doi-asserted-by":"publisher","first-page":"18374","DOI":"10.18632\/oncotarget.4073","volume":"6","author":"TX Lu","year":"2015","unstructured":"Lu TX, Fan L, Wang L, Wu JZ, Miao KR, Liang JH, Gong QX, Wang Z, Young KH, Xu W, Zhang ZH, Li JY (2015) MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget 6:18374\u201318388","journal-title":"Oncotarget"},{"issue":"1","key":"4124_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"27","key":"4124_CR17","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"B Cheson","year":"2014","unstructured":"Cheson B, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea; German High-Grade Lymphoma Study Group; German Hodgkin\u2019s Study Group; Japanese Lymphoma Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"15","key":"4124_CR18","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Whyman JD SKA, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske T, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun H, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS (2014) Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124(15):2354\u20132361","journal-title":"Blood"},{"issue":"4","key":"4124_CR19","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjh.13463","volume":"170","author":"Howlett","year":"2015","unstructured":"Howlett, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A (2015) Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 170(4):504\u2013514","journal-title":"Br J Haematol"},{"key":"4124_CR20","unstructured":"Phillips EH, Burton C, Kirkwood AA, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna K, Montoto S, Paneesha S, Clifton-Hadley L, Linch D, Andrew McMillan A (2018) Favourable outcomes with R-CODOX-M\/R-IVAC across all subgroups of aggressive high grade B-cell lymphoma: pathology and updated survival results from a UK phase 2 UK NCRI\/Bloodwise trial. European Haemaotology Association Annual Meeting, Abst. 1548"},{"issue":"12","key":"4124_CR21","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","volume":"5","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Roschewski MC, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH (2018) Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 5(12):e609\u2013e617","journal-title":"Lancet Haematol"},{"key":"4124_CR22","doi-asserted-by":"crossref","unstructured":"Johnson P, Balasubramanian S, Hodkinson B, Schaffer M, Parisi L, Shreeve SM, Sun S, Vermeulen J, Sehn LH, Staudt L, Younes A, Wilson W (2019) Clinical impact of ibrutinib with R-CHOP in untreated non-GCB DLBCL co-expressing BCL2 and MYC genes in the phase 3 Phoenix trial. ASH Annual Meeting 2019, Session 626:354","DOI":"10.1182\/blood-2019-124443"},{"issue":"21","key":"4124_CR23","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Sch\u00f6der H, Zelenetz AD, Leonard JP (2019) Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303. J Clin Oncol 37(21):1790\u20131799","journal-title":"J Clin Oncol"},{"issue":"5","key":"4124_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Tr\u00fcmper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690","journal-title":"Nat Med"},{"key":"4124_CR25","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407","journal-title":"N Engl J Med"},{"issue":"3","key":"4124_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.18.01314","volume":"37","author":"C Sha","year":"2019","unstructured":"Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, Thompson JS, Uddin R, Worrillow L, Chalkley R, van Hoppe M, Ahmed S, Maishman T, Caddy J, Schuh A, Mamot C, Burton C, Tooze R, Davies A, Du MQ, Johnson PWM, Westhead DR (2019) Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy. J Clin Oncol 37(3):202\u2013212","journal-title":"J Clin Oncol"},{"issue":"3","key":"4124_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW (2019) Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol 37(3):190\u2013201","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04124-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04124-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04124-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T02:14:51Z","timestamp":1625105691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04124-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["4124"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04124-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the ICH-GCP guidelines and the declaration of Helsinki. Ethical approval was obtained from the ethical committee of the Medical University of Innsbruck, and all patients gave an informed consent for study participation (EK-Nr.1213\/2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}